Investing in solid dividend stocks can help navigate the uncertain economic environment we face. Regular payouts can help ...
Amgen Inc.'s healthy commercial product portfolio and pipeline position the company well for long-term value creation. Read ...
Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff ...
The competition to develop obesity treatments that are more convenient and powerful than Wegovy and Mounjaro is intensifying. Since the popularization ...
Zacks Investment Research on MSN
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk NVO announced positive data from a sub-analysis of its phase III REDEFINE 1 study assessing the efficacy and safety of once-weekly cagrilintide 2.4 mg as a monotherapy, alongside ...
Dr. Osama Hamdy, the acclaimed Egyptian physician at Harvard who consistently educates the public on medical breakthroughs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback